Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Thailand Inflation Remains Negative for 10th Straight Month in January 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Eli Lilly to Introduce Mounjaro Weight-Loss Drug in Hong Kong by Year-End
Global pharmaceutical giant Eli Lilly is gearing up to launch its weight-loss drug, Mounjaro, in Hong Kong by the end of this year. According to a report from Bloomberg News, the company has received approval from Hong Kong's government to sell its tirzepatide injections under the Mounjaro brand.
Mounjaro for Weight Management and Diabetes
Eli Lilly's Mounjaro is designed for both long-term weight management and the treatment of type 2 diabetes. It will be available on the Kwikpen device, which allows for easy self-administration. The company aims to address the growing demand for effective weight-loss treatments while continuing to provide solutions for diabetes management.
Hong Kong Market Entry
Hong Kong marks a strategic entry point for Eli Lilly as it expands its global presence. With the approval of Mounjaro, the company is poised to offer a highly anticipated solution for individuals struggling with obesity and related health issues. The weight-loss sector has seen significant growth in recent years, and Mounjaro is expected to make a notable impact.
